country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-174415

Copy Link Print Information

ZSH-2117

ZSH-2117 is an NEDD4-recruiting EGFR PROTAC degrader. ZSH-2117 shows an IC₅₀ of 13 nM against EGFR^{L858R/T790M/C797S}, induces EGFR proteasome-dependent degradation, inhibits the downstream signaling pathways of EGFR, including the phosphorylation of AKT and ERK, suppresses cancer cell proliferation, and exhibits in vivo anti-tumor activity. ZSH-2117 can be used in research related to non-small cell lung cancer.
(Pink: EGFR ligand (HY-175162); Blue: NEDD4 ligand (HY-175159); Black: linker).

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

화학식: C₃₆H₃₉BrClN₈O₂P
분자량:762.08

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (284 KB)

ZSH-2117 Chemical Structure

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Use of MCE Products

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

ZSH-2117 is an NEDD4-recruiting EGFR PROTAC degrader. ZSH-2117 shows an IC₅₀ of 13 nM against EGFR^{L858R/T790M/C797S}, induces EGFR proteasome-dependent degradation, inhibits the downstream signaling pathways of EGFR, including the phosphorylation of AKT and ERK, suppresses cancer cell proliferation, and exhibits in vivo anti-tumor activity. ZSH-2117 can be used in research related to non-small cell lung cancer^[1]. (Pink: EGFR ligand (HY-175162); Blue: NEDD4 ligand (HY-175159); Black: linker).

IC₅₀ & Target

^[1]

EGFR^{L858R/T790M/C797S}

13 nM (IC₅₀)

All PROTACs Isoforms :

All EGFR Isoforms :

All Akt Isoforms :

All ERK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
BaF3	DC₅₀	45 nM	Half-maximal degradation concentration of EGFR^{L858R/T790M/C797S} in Ba/F3-EGFR^{L858R/T790M/C797S} cells assessed by Western blot analysis after 8 h of treatment. Half-maximal degradation concentration of EGFR^{L858R/T790M/C797S} in Ba/F3-EGFR^{L858R/T790M/C797S} cells assessed by Western blot analysis after 8 h of treatment.	40506832
NCI-H1975	DC₅₀	149 nM	Half-maximal degradation concentration of FLAG-EGFR^{L858R/T790M/C797S} in H1975-FLAG-EGFR^{L858R/T790M/C797S} cells assessed by Western blot analysis after 8 h of treatment. Half-maximal degradation concentration of FLAG-EGFR^{L858R/T790M/C797S} in H1975-FLAG-EGFR^{L858R/T790M/C797S} cells assessed by Western blot analysis after 8 h of treatment.	40506832
BaF3	IC50	13 nM	Half-maximal inhibitory concentration for proliferation inhibition in Ba/F3-EGFR^{L858R/T790M/C797S} cells assessed via cell viability measurement. Half-maximal inhibitory concentration for proliferation inhibition in Ba/F3-EGFR^{L858R/T790M/C797S} cells assessed via cell viability measurement.	40506832

In Vitro

ZSH-2117 (0.001-100 μM) potently inhibits the proliferation of Ba/F3-EGFR^{L858R/T790M/C797S} cells, with an IC₅₀ of 13 nM^[1].
ZSH-2117 (0.2 μM; 8 h) potently degrades EGFR^{L858R/T790M/C797S} in Ba/F3-EGFR^{L858R/T790M/C797S} cells^[1].
ZSH-2117 (25-200 nM; 8 h) potently induces concentration-dependent degradation of EGFR^{L858R/T790M/C797S} in Ba/F3-EGFR^{L858R/T790M/C797S} cells, with a DC₅₀ of 45 nM and a maximum degradation rate of 96%^[1].
ZSH-2117 (100 nM; 10 h)-mediated degradation of EGFR^{L858R/T790M/C797S} in Ba/F3-EGFR^{L858R/T790M/C797S} cells relies on the proteasome, the activity of E1 ligase, and requires binding to EGFR^{L858R/T790M/C797S}^[1].
ZSH-2117 (0.5 μM; 3 h) competes with probe AZ9-1 for binding to the E3 ligase NEDD4 in Ba/F3-EGFR^{L858R/T790M/C797S} cells^[1].
ZSH-2117 (0.1-3 μM; 8 h) potently induces concentration-dependent degradation of FLAG-EGFR^{L858R/T790M/C797S} in H1975-FLAG-EGFR^{L858R/T790M/C797S} cells, with a DC₅₀ of 149 nM and a maximum degradation rate of 94%^[1].
The NEDD4-dependent degradation of FLAG-EGFR^{L858R/T790M/C797S} mediated by ZSH-2117 (0.2 μM; 8 h) occurs in H1975-FLAG-EGFR^{L858R/T790M/C797S} cells^[1].
ZSH-2117 (0.2 μM; 8 h)-mediated degradation of FLAG-EGFR^{L858R/T790M/C797S} and formation of the EGFR-NEDD4 ternary complex in H1975-FLAG-EGFR^{L858R/T790M/C797S} cells depend on the C1286 residue of NEDD4^[1].
ZSH-2117 (0.5 μM; 4 h) covalently binds to the cysteine residue C1286 on the surface of NEDD4 in H1975 cells expressing HA-NEDD4-EGFR^{L858R/T790M/C797S}^[1].
ZSH-2117 (25-500 nM; 8 h) inhibits the downstream signaling pathways of EGFR (phosphorylation of AKT and ERK) in Ba/F3-EGFR^{L858R/T790M/C797S} cells in a concentration-dependent manner in vitro, and simultaneously induces the degradation of EGFR^{L858R/T790M/C797S}^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

Ba/F3-EGFR^{L858R/T790M/C797S}
Concentration:

0.2 μM
Incubation Time:

8 h
Result:

Exhibited the highest degradation activity for EGFR^{L858R/T790M/C797S} among tested analogs.
Reduced protein levels to a significantly lower percentage of control than DMSO, ZSH-1136, ZSH-2155, ZSH-2158, and ZSH-3005.

Western Blot Analysis^[1]

Cell Line:

Ba/F3-EGFR^{L858R/T790M/C797S}
Concentration:

25, 50, 100, 200 nM
Incubation Time:

8 h
Result:

Induced concentration-dependent degradation of EGFR^{L858R/T790M/C797S}.
Achieved a half-maximal degradation concentration (DC₅₀) of 45 nM.
Reached a maximum degradation (D_max) of 96%.

Western Blot Analysis^[1]

Cell Line:

Ba/F3-EGFR^{L858R/T790M/C797S}
Concentration:

100 nM
Incubation Time:

10 h
Result:

Attenuated EGFR^{L858R/T790M/C797S} degradation.
Showed no effect on EGFR^{L858R/T790M/C797S} degradation.
Blocked EGFR^{L858R/T790M/C797S} degradation.

Western Blot Analysis^[1]

Cell Line:

H1975-FLAG-EGFR^{L858R/T790M/C797S}
Concentration:

0.1, 0.3, 1, 3 μM
Incubation Time:

8 h
Result:

Induced concentration-dependent degradation of FLAG-EGFR^{L858R/T790M/C797S}.
Achieved a half-maximal degradation concentration (DC₅₀) of 149 nM.
Reached a maximum degradation (D_max) of 94%.

Western Blot Analysis^[1]

Cell Line:

H1975-FLAG-EGFR^{L858R/T790M/C797S}
Concentration:

0.2 μM
Incubation Time:

8 h
Result:

Completely eliminated ZSH-2117-induced degradation of FLAG-EGFR^{L858R/T790M/C797S} with knockdown of NEDD4.
Showed significant degradation of FLAG-EGFR^{L858R/T790M/C797S} in shScramble control cells.
Completely blocked ZSH-2117-induced degradation of FLAG-EGFR^{L858R/T790M/C797S} with NEDD4 C1286A mutant.
Abolished the interaction between NEDD4 and FLAG-EGFR^{L858R/T790M/C797S} with NEDD4 C1286A mutant.

Western Blot Analysis^[1]

Cell Line:

Ba/F3-EGFR^{L858R/T790M/C797S}
Concentration:

25, 50, 100, 200, 500 nM
Incubation Time:

8 h
Result:

Induced concentration-dependent reductions in p-EGFR, p-AKT(S473), and p-ERK levels.
Corresponded reduced EGFR^{L858R/T790M/C797S} protein levels with decreased downstream signaling levels.

In Vivo

ZSH-2117 (2.5 mg/kg; i.p.; administered on days 0, 3, 5 and 7) exhibits potent in vivo antitumor activity in Ba/F3-EGFR^{L858R/T790M/C797S} xenograft mice, with a 65% tumor growth inhibition rate, while maintaining minimal effects on body weight^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOD-SCID mice^[1]
Dosage:

2.5 mg/kg
Administration:

i.p.; administered on days 0, 3, 5 and 7
Result:

Achieved a tumor growth inhibition (TGI) rate of 65%.
Significantly reduced tumor volume and tumor weight relative to vehicle control.
Degraded EGFRL858R/T790M/C797S protein in tumor tissues.
Had minimal impact on mouse body weight.

Chemical Information

분자량 762.08
화학식 C₃₆H₃₉BrClN₈O₂P
SMILES

O=C(N1CCN(C2CCN(C3=CC=C(NC4=NC=C(Cl)C(NC5=CC=CC=C5P(C)(C)=O)=N4)C=C3Br)CC2)CC1)C6N=C6C7=CC=CC=C7
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. He X, et al. Covalent Recruitment of NEDD4 for Targeted Protein Degradation: Rational Design of Small Molecular Degraders. Journal of the American Chemical Society. 2025 Jun 25;147(25):21512-21525. [Content Brief]

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기

Amount: USD 0.00

Biological Activity
- 제품 설명
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
순도&문서
References

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

ZSH-2117

All PROTACs Isoforms

All EGFR Isoforms

All Akt Isoforms

All ERK Isoforms

Biological Activity

제품 설명

IC50 & Target

Cellular Effect

In Vitro

In Vivo

Chemical Information

순도&문서

References

Calculators

Help & FAQs

ZSH-2117 Related Classifications

HY-174415 Related Classifications

Bioz

Keywords

Your Recently Viewed Products

IC₅₀ & Target